Active Ingredient(s): Opicapone
FDA Approved: * April 24, 2020
Pharm Company: * NEUROCRINE
Category: Parkinsons

Opicapone, sold under the brand name Ongentys, is a medication which is administered together with levodopa in people with Parkinson's disease.[4] The most common side effects are dyskinesia (difficulty controlling movement), constipation, increased blood creatine kinase, hypotension/syncope, and decreased weight.[3][5] Opicapone, works to restore the levels of dopamine in the parts of the brain that control movement and coordination.[4&... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Ongentys 25 mg Oral Capsule
NDC: 70370-3025
Neurocrine Biosciences, Inc.
Ongentys 50 mg Oral Capsule
NDC: 70370-3050
Neurocrine Biosciences, Inc.